1. USP39 stabilizes β-catenin by deubiquitination and suppressing E3 ligase TRIM26 pre-mRNA maturation to promote HCC progression
   Weiwei Wang et al, 2023, Cell Death & Disease CrossRef
2. Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma
   Lanqian Su et al, 2024, Frontiers in Pharmacology CrossRef
3. Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
   Kenta Motomura et al, 2023, Cancers CrossRef
4. Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations
   Tomoko Aoki et al, 2024, Liver Cancer CrossRef
5. PD-1/PD-L1 and DNA Damage Response in Cancer
   Mateusz Kciuk et al, 2023, Cells CrossRef
6. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
   Anand V. Kulkarni et al, 2023, eClinicalMedicine CrossRef
7. Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
   Wiebke Werner et al, 2024, Seminars in Liver Disease CrossRef
8. Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
   Nobuaki Ishihara et al, 2024, Hepatology Research CrossRef
9. Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
   Stefania De Lorenzo et al, 2022, Cancers CrossRef
10. Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
    Ji Won Han et al, 2023, International Journal of Molecular Sciences CrossRef
11. Systemic Therapies for Hepatocellular Carcinoma in India
    Vinay Jahagirdar et al, 2024, Journal of Clinical and Experimental Hepatology CrossRef